JP2023548136A5 - - Google Patents

Info

Publication number
JP2023548136A5
JP2023548136A5 JP2023526186A JP2023526186A JP2023548136A5 JP 2023548136 A5 JP2023548136 A5 JP 2023548136A5 JP 2023526186 A JP2023526186 A JP 2023526186A JP 2023526186 A JP2023526186 A JP 2023526186A JP 2023548136 A5 JP2023548136 A5 JP 2023548136A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
agonists
product according
linker
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548136A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057291 external-priority patent/WO2022094237A1/en
Publication of JP2023548136A publication Critical patent/JP2023548136A/ja
Publication of JP2023548136A5 publication Critical patent/JP2023548136A5/ja
Pending legal-status Critical Current

Links

JP2023526186A 2020-10-30 2021-10-29 酵素活性化血清半減期延長型治療用コンジュゲート Pending JP2023548136A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108046P 2020-10-30 2020-10-30
US63/108,046 2020-10-30
US202163197935P 2021-06-07 2021-06-07
US63/197,935 2021-06-07
PCT/US2021/057291 WO2022094237A1 (en) 2020-10-30 2021-10-29 Enzyme activated serum extended half-life therapeutic conjugates

Publications (2)

Publication Number Publication Date
JP2023548136A JP2023548136A (ja) 2023-11-15
JP2023548136A5 true JP2023548136A5 (cg-RX-API-DMAC7.html) 2024-09-20

Family

ID=81383295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526186A Pending JP2023548136A (ja) 2020-10-30 2021-10-29 酵素活性化血清半減期延長型治療用コンジュゲート

Country Status (5)

Country Link
US (1) US20230381330A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548136A (cg-RX-API-DMAC7.html)
KR (1) KR20230141755A (cg-RX-API-DMAC7.html)
WO (1) WO2022094237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2025259853A1 (en) * 2024-06-12 2025-12-18 Yale University Multiplexed assemblies of proteins for targeted drug and gene delivery
WO2026002995A1 (en) 2024-06-24 2026-01-02 Avacta Life Sciences Limited Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof
WO2026002988A1 (en) * 2024-06-24 2026-01-02 Avacta Life Sciences Limited Fibroblast activation protein alpha binder proteins
CN119684406A (zh) * 2024-12-18 2025-03-25 东南大学 一种荷载喜树碱的酶响应自组装多肽前药、其制备及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
JP6539729B2 (ja) * 2014-06-03 2019-07-03 ジアリー・ファーマシューティカルズ・インコーポレイテッドJiaray Pharmaceuticals, Inc. ペプチド−薬物複合体
IL325256A (en) * 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
US20210353652A1 (en) * 2018-06-04 2021-11-18 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
JP2023548310A (ja) * 2020-10-30 2023-11-16 アバクタ・ライフ・サイエンシーズ・リミテッド Fap活性化血清半減期延長型治療用コンジュゲート

Similar Documents

Publication Publication Date Title
JP2023041829A (ja) セリンプロテアーゼ分子および療法
AU2001275226B2 (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7291673B2 (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
Gong et al. Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy
EP2310029B1 (en) Fusion proteins for use in the treatment of cancer
AU2006260914B2 (en) N, N-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs
JP2023548310A5 (cg-RX-API-DMAC7.html)
US20240424129A1 (en) Recombinant fusion antibody, and antibody-drug conjugate and use thereof
US20180125988A1 (en) Targeted xten conjugate compositions and methods of making same
WO2019126240A1 (en) Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
AU2021297984B2 (en) HER-2 targeted bispecific compositions and methods for making and using the same
JP2018500049A5 (cg-RX-API-DMAC7.html)
JP2008231107A (ja) 抗血管新生性ポリペプチド及び血管新生を抑制するための方法
EP4090673A1 (en) Cytokine il-2 prodrugs comprising a cleavable linker
JP2023548136A (ja) 酵素活性化血清半減期延長型治療用コンジュゲート
TW202227139A (zh) Fap活化之血清延長半衰期治療結合物
WO2011005098A1 (en) Peptide ligands for targeting to the blood-brain barrier
Su et al. Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles
RU2851152C1 (ru) Нацеленные на her-2 биспецифические композиции и способы их получения и применения
WO2026078691A1 (en) Matrix metalloproteinase inhibitors and uses thereof
Zuppone Development of saporin-based therapeutic options for the treatment of solid tumors.
Li et al. Peptides as multifunctional linchpins in targeted drug conjugates
WO2026080026A1 (en) Antibody drug conjugates
CN116963781A (zh) 酶激活的血清延长半衰期治疗性缀合物
TW202237667A (zh) 靶向her-2之雙特異性組合物以及其製造及使用方法